Table 3.
Studies comparing surgery vs EBRT vs EBRT + BT in high‐risk prostate cancer
| Study | Data source | Year of diagnosis | Age (years) | Patient no. (RP/EBRT/EBRT + BT) | Group of comparisons | Result (CSS) | Result (OS) |
|---|---|---|---|---|---|---|---|
| Berg, 2018 | NCDB | 2004‐2010 | ≤ 65 | 13 985 (12 283/0/1702) | EBRT + BT vs RP | NA | Favor RP |
| Kishan, 2018 | Multi‐institutions | 2000‐2013 | All age | 1809 (639/734/436) | EBRT + BT vs EBRT vs RP | Favor EBRT + BT |
≤7.5 y, favor EBRT + BT >7.5 y, no difference |
| Ennis, 2018 | NCDB | 2004‐2013 | All age | 42 765 (24 688/15 435/2642) | EBRT + BT vs EBRT vs RP | NA |
Equal EBRT + BT vs RP EBRT inferior |
| Ours, 2019 | SEER | 2004‐2015 | All age | 62 533 (59 540/2638/355) | EBRT + BT vs EBRT vs RP | favor EBRT + BT | EBRT inferior |
Comparison: EBRT vs Surgery; EBRT + BT vs Surgery; EBRT + BT vs EBRT.